JP2022530438A5 - - Google Patents

Info

Publication number
JP2022530438A5
JP2022530438A5 JP2021563155A JP2021563155A JP2022530438A5 JP 2022530438 A5 JP2022530438 A5 JP 2022530438A5 JP 2021563155 A JP2021563155 A JP 2021563155A JP 2021563155 A JP2021563155 A JP 2021563155A JP 2022530438 A5 JP2022530438 A5 JP 2022530438A5
Authority
JP
Japan
Prior art keywords
variable region
amino acid
antibody
pharmaceutical composition
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021563155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530438A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029657 external-priority patent/WO2020219775A1/en
Publication of JP2022530438A publication Critical patent/JP2022530438A/ja
Publication of JP2022530438A5 publication Critical patent/JP2022530438A5/ja
Withdrawn legal-status Critical Current

Links

JP2021563155A 2019-04-24 2020-04-23 抗ｃｄ１１７抗体薬物複合体およびその使用 Withdrawn JP2022530438A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838293P 2019-04-24 2019-04-24
US62/838,293 2019-04-24
PCT/US2020/029657 WO2020219775A1 (en) 2019-04-24 2020-04-23 Anti-cd117 antibody-drug conjugates and uses thereof

Publications (2)

Publication Number Publication Date
JP2022530438A JP2022530438A (ja) 2022-06-29
JP2022530438A5 true JP2022530438A5 (enExample) 2023-05-01

Family

ID=72940987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563155A Withdrawn JP2022530438A (ja) 2019-04-24 2020-04-23 抗ｃｄ１１７抗体薬物複合体およびその使用

Country Status (4)

Country Link
US (1) US20220175944A1 (enExample)
EP (1) EP3958909A4 (enExample)
JP (1) JP2022530438A (enExample)
WO (1) WO2020219775A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
EP3958878A4 (en) * 2019-04-24 2022-12-28 Magenta Therapeutics, Inc. CONDITIONING METHODS FOR GENE THERAPY
JP2022530442A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド アントラサイクリン抗体薬物複合体およびその使用
WO2022132929A2 (en) * 2020-12-16 2022-06-23 Vera Therapeutics, Inc. Multispecific antibody molecules and uses thereof
WO2022187050A1 (en) * 2021-03-01 2022-09-09 BioLegend, Inc. Anti-cd117 agents and compositions and methods for making and using the same
CN117683079B (zh) * 2023-12-12 2025-04-04 九洲药业(杭州)有限公司 一种抗体偶联药物连接子的固相合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006532A1 (en) * 2001-03-20 2004-01-08 David Lawrence Network access risk management
EP3255061B1 (en) * 2006-11-03 2021-06-16 The Board of Trustees of the Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
EP4063391A1 (en) * 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2015112822A1 (en) * 2014-01-24 2015-07-30 Kolltan Pharmaceuticals, Inc. Antibody-drug conjugates targeting kit receptor and uses thereof
HK1256681A1 (zh) * 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
EP3310932B1 (en) * 2015-06-17 2023-08-30 The UAB Research Foundation Crispr/cas9 complex for genomic editing
PT3370768T (pt) * 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
US10111966B2 (en) * 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
JP2021526525A (ja) * 2018-06-07 2021-10-07 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法
AU2019374055B2 (en) * 2018-10-30 2026-06-11 Regeneron Pharmaceuticals, Inc. Methods for allogeneic hematopoietic stem cell transplantation

Similar Documents

Publication Publication Date Title
JP2022530089A5 (enExample)
ES2795818T3 (es) Anticuerpos CD48 y conjugados de los mismos
US11819553B2 (en) Glypican 3 antibodies and conjugates thereof
ES2814227T3 (es) Anticuerpos anti-CD123 y conjugados de los mismos
EP3107557B1 (en) Hydrophilic antibody-drug conjugates
CN101903403B (zh) Cd19结合剂及其应用
JP2022548908A (ja) カンプトテシン誘導体及びその複合体
RU2010130977A (ru) Иммуноконъюгаты, направленные на cd138, и их применение
HK1245802A1 (zh) 多特异性抗体、抗体类似物、组合物和方法
JP2025183307A5 (enExample)
JP2022512778A5 (enExample)
JP2021513844A5 (enExample)
PT2099823E (pt) Agentes de ligação ao alvo variantes e suas utilizações
RU2018130757A (ru) Конъюгаты антитела к cd74, композиции, содержащие конъюгаты антитела к cd74, и способы использования конъюгатов антитела к cd74
JP2012522513A5 (enExample)
JP2023532380A (ja) 二成分毒素を担った抗体薬物複合体及びその応用
JP2022512781A5 (enExample)
CA3156096C (en) Pd1 and vegfr2 dual-binding agents
JP2023520399A5 (enExample)
JP2022530442A5 (enExample)
US20240101668A1 (en) Polypeptides and their use in treatment of disease
JP2018138538A (ja) リンカー−薬物およびこれを用いた抗体−薬物複合体（ａｄｃ）
WO2024235130A1 (zh) 多环化合物及其制备方法和用途
CN120417932A (zh) 接头-有效载荷化合物、偶联物及其应用
CN120957759A (zh) 具有抗肿瘤作用的化合物及其制备方法和用途